BIIB Stock Analysis: Buy, Sell, or Hold?
BIIB - Biogen Inc. Common Stock
$188.08
-1.86 (-0.98%)
▼
5d:
+0.03%
30d:
+6.4%
90d:
+4.38%
BUY
MODERATE Confidence
Analysis Updated: Mar 5, 2026 12:00 AM ET
Earnings: May 06, 2026
Smart Money Accumulation
BIIB is down 6.5% this week, but smart money is accumulating calls. Top strike: $180 2026-04-17 with 393 OI. Call ratio: 90% View Scanner →
Strength: 7.3/10
Get Alerted When BIIB Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
💡 BUY OPPORTUNITY: BIIB shows positive signals but monitor for confirmation. Market pricing in 0.2% annual growth which appears achievable. Moderate conviction.
💡 BUY OPPORTUNITY: BIIB shows positive signals but monitor for confirmation. Market pricing in 0.2% annual growth which appears achievable. Moderate conviction.
Long-Term Wealth Forecast (2031)
Based on Analyst Consensus Growth & Historical Valuation
0% (Stagnation)
50% (Hyper Growth)
EST. PRICE IN 2031
$226.46
Based on 3.8% avg growth
INTRINSIC VALUE TODAY
$140.61
Trading above fair value
How this is calculated: We use a Growth Decay Model: starting with analyst consensus growth (adjusted above) and gradually slowing it down to a long-term terminal rate (4%) by Year 5. This provides a more realistic valuation than assuming constant hyper-growth. We then apply a 11.6x Exit PE.
In-depth Analysis How we analyze
Valuation Analysis: BIIB is currently trading at $188.08, which is considered fair relative to its 30-day fair value range of $180.11 to $195.46. The stock's valuation (Forward PE: 11.7) is in line with its historical norms (11.6). At these levels, the market is pricing in 0.2% annual earnings growth. This growth rate appears achievable given the company's track record, suggesting the valuation is rational.
Technical Outlook: Technically, BIIB is in a strong uptrend. Immediate support is located at $181.79, while resistance sits at $198.72.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, BIIB is in a strong uptrend. Immediate support is located at $181.79, while resistance sits at $198.72.
Market Sentiment: The stock shows a mixed technical setup (40/100), with neutral trendline and momentum signals. In the options market, Implied Volatility is low (0th percentile), suggesting options premiums are relatively cheap. This makes it an attractive time for long options strategies if you have a directional bias. Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
FAIR
Fair Price Range
$180.11 -
$195.46
Company Quality Score
57/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
74.6%
All Signals
- NEUTRAL: Price in fair range
- BULLISH: Options cheap (IV 0th percentile)
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- NEUTRAL: Near Wall St target ($205.67)
- NEUTRAL: Market pricing in 0.2% annual earnings growth - fairly valued
Fair Price Analysis
30-Day Fair Range
$180.11 -
$195.46
Current vs Fair Value
FAIR
Expected Move (7 Days)
±$8.58
(4.6%)
Support & Resistance Levels
Support Level
$181.79
Resistance Level
$198.72
Current Trend
Strong Uptrend
Technical data as of
Mar 5, 2026
Fundamental Context
Forward P/E (Next Year Est.)
11.70
Wall Street Target
$205.67
(+8.3%)
Revenue Growth (YoY)
-7.1%
Earnings Growth (YoY)
19.2%
Profit Margin
13.1%
Valuation Premium vs History
+0.2% premium
PE vs Historical
11.7 vs 11.6
FAIR
Market-Implied Price Targets
If current PE multiple persists
Implied Growth (YoY):
+0.2%
(market-implied from PE analysis)
1-Year Target
$190.32
(+0%)
2-Year Target
$190.70
(+0%)
3-Year Target
$191.08
(+1%)
3-Yr Target (if PE normalizes)
(PE: 12→12)
PE COMPRESSION
$189.52
(0%)
Earnings growth offset by PE compression
3-Year Scenarios
Using analyst projected EPS growth
Bull:
(PE: 22.6, Growth: 3.5%)
$407.16
(+114%)
Base:
(SPY PE: 11.7, Growth: 3.5%)
$210.80
(+11%)
Bear:
(PE: 9.9, Growth: 3.5%)
$179.18
(-6%)
📈
Valuation based on Current Earnings
RECOVERY PLAY: Stock looks expensive now (21x PE), but valuation improves significantly next year (12x PE) as earnings recover.
Trailing PE: 21.37 | Current EPS (TTM): $8.80
Bull Case
$381.69
(+99%)
Analyst growth 84.5%, PE expands to 23.5
Base Case
$346.99
(+81%)
Market implied 84.5%, PE stable at 21.4
Bear Case
$127.85
(-33%)
Severe decline -20.0%, PE contracts to 18.2
These are projections based on PE multiples and EPS growth scenarios, not predictions. Actual results may vary significantly.
Share & Embed Analysis
Last updated: March 06, 2026 5:12 AM ET
Data refreshes hourly during market hours. Next update: 6:12 AM
Data refreshes hourly during market hours. Next update: 6:12 AM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is BIIB showing a specific setup today?
Insider Activity (6 Months)
3
Buys
2
Sells
+
Net
INSIDERS SELLING
Recent Transactions
Nicole Murphy
BUY
3 shares
2026-02-12
Priya Singhal
SELL
2660 shares
2026-02-09
Priya Singhal
SELL
748 shares
2026-02-02
Top Rated Drug Manufacturers - General Stocks
Top-rated stocks in Drug Manufacturers - General by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
LLY
Eli Lilly and Company |
STRONG BUY
29 analysts |
$1211 | 51 HOLD |
|
GILD
Gilead Sciences Inc |
BUY
30 analysts |
$155 | 61 BUY |
|
ABBV
AbbVie Inc |
BUY
28 analysts |
$248 | 67 BUY |
|
AMGN
Amgen Inc |
HOLD
32 analysts |
$350 | 55 HOLD |
|
MRK
Merck & Company Inc |
BUY
26 analysts |
$126 | 60 HOLD |
Advanced BIIB Option Strategies
Professional options setups generated by AI based on today's BIIB price and gamma walls.
